BE890136A - Nouveaux agents myotonolytiques a base de 4,5,6,7-tetra-hydroisoxazolo(5,4-c)pyridine-3-ols - Google Patents

Nouveaux agents myotonolytiques a base de 4,5,6,7-tetra-hydroisoxazolo(5,4-c)pyridine-3-ols

Info

Publication number
BE890136A
BE890136A BE1/10302A BE1010302A BE890136A BE 890136 A BE890136 A BE 890136A BE 1/10302 A BE1/10302 A BE 1/10302A BE 1010302 A BE1010302 A BE 1010302A BE 890136 A BE890136 A BE 890136A
Authority
BE
Belgium
Prior art keywords
hydroisoxazolo
myotonolytic
ols
tetra
pyridine
Prior art date
Application number
BE1/10302A
Other languages
English (en)
Original Assignee
Sandoz Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Sa filed Critical Sandoz Sa
Publication of BE890136A publication Critical patent/BE890136A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BE1/10302A 1980-09-01 1981-08-28 Nouveaux agents myotonolytiques a base de 4,5,6,7-tetra-hydroisoxazolo(5,4-c)pyridine-3-ols BE890136A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8028199 1980-09-01

Publications (1)

Publication Number Publication Date
BE890136A true BE890136A (fr) 1982-03-01

Family

ID=10515772

Family Applications (1)

Application Number Title Priority Date Filing Date
BE1/10302A BE890136A (fr) 1980-09-01 1981-08-28 Nouveaux agents myotonolytiques a base de 4,5,6,7-tetra-hydroisoxazolo(5,4-c)pyridine-3-ols

Country Status (6)

Country Link
US (1) US4362731A (fr)
JP (1) JPS5777618A (fr)
AU (1) AU555504B2 (fr)
BE (1) BE890136A (fr)
IT (1) IT1138543B (fr)
PH (1) PH17018A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2219295B (en) * 1988-06-03 1992-10-07 Wyeth John & Brother Ltd Use of gamma amino butyric acid autoreceptor agonists for the manufacture of medicaments

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2159624T3 (es) * 1993-12-28 2001-10-16 Allergan Sales Inc Toxinas botulinicas para el tratamiento de la hiperhidrosis.
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020119168A1 (en) * 2001-02-20 2002-08-29 Rudnic Edward M. Therapeutic agent delivery
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1653925A1 (fr) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Pastille robuste
WO2005016278A2 (fr) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotique, utilisation et formulation associees
WO2005023184A2 (fr) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Produit antibiotique, son utilisation et sa formulation
US8460710B2 (en) 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
EP1761263A1 (fr) * 2004-06-29 2007-03-14 H. Lundbeck A/S Traitement de douleur neuropathique, de fibromyalgie ou de polyarthrite rhumatoide
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2017516868A (ja) 2014-06-06 2017-06-22 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 持続性抑制を増加させ、二次性不眠症を治療する方法
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
WO2018031748A1 (fr) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methodes et compositions pour le traitement de troubles épileptiques
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
EP3648762A4 (fr) 2017-08-04 2021-03-24 Ovid Therapeutics, Inc. Utilisation de gaboxadol dans le traitement du diabète et d'états apparentés
WO2020061410A1 (fr) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Utilisation de gaboxadol pour le traitement du syndrome de gilles de la tourette, de tics et du bégaiement
GB2594616A (en) 2018-11-21 2021-11-03 Certego Therapeutics Inc Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2219295B (en) * 1988-06-03 1992-10-07 Wyeth John & Brother Ltd Use of gamma amino butyric acid autoreceptor agonists for the manufacture of medicaments

Also Published As

Publication number Publication date
IT1138543B (it) 1986-09-17
US4362731A (en) 1982-12-07
PH17018A (en) 1984-05-11
JPS5777618A (en) 1982-05-15
AU7478181A (en) 1982-03-11
IT8123700A0 (it) 1981-08-31
AU555504B2 (en) 1986-09-25

Similar Documents

Publication Publication Date Title
BE890136A (fr) Nouveaux agents myotonolytiques a base de 4,5,6,7-tetra-hydroisoxazolo(5,4-c)pyridine-3-ols
DE3577277D1 (de) Uebungsgeraet.
FI831664A0 (fi) 1,3-dioxan-5-ylalkenoylsyror
DK587183A (da) 1,4-benzodiazepin-derivater
ES265246Y (es) Un pasador de sujecion.
FI850275L (fi) Nya 6-susbtituerade furo-(3,4-c) -pyridinderivat.
NO160564C (no) Treningsapparat.
IT1194789B (it) 25-idrossi-26,26,26,27,27,27-esafluorocolecalciferolo
DK284481A (da) 10-(1,2-propadiennyl) steroider
DE3166949D1 (de) Antiinflammatory 4,5-diaryl-alpha-polyfluoroalkyl-1h-imidazole-2-methanamines
TR20923A (tr) Izoksazolilbenzamidler
FI854178L (fi) 1,2,4-triazolo-karbamat och dess syraadditionssalter, foerfarande foer deras framstaellning och laekemedel.
FI812803L (fi) Penisillanoyloximetyl penicillanat 1,1,1',1'-tetraoxid
IT8121126A0 (it) 1 alfa-idrossi-2beta-fluorocolecalciferolo.
DK155594C (da) 3,3-dimethyl-1-phenoxybutan-2-oler
FI811967L (fi) 2,3-bis-hydroxibenzylderivat
DE3365097D1 (de) 6,7-dihydro-7,7-disubstituted-khellins
ES262334Y (es) "un peine".
FI812210L (fi) Stabiliserade 1,1,1-trikloretansammansaettningar
IT1172389B (it) 2,2,2-trialogeno-1-(trialogenometil)etiliden-bis-benzen-tioli
DE3576334D1 (de) 1,2,3,3a,8,8a-hexahydro-indeno-(1,2-c)pyrrde.
DE3360666D1 (de) 2,6-dicyanoanilines
DE3175752D1 (de) 1,3-dihalopropan-2-ols
FI810242L (fi) 1,3-diformyloxi-2-brom-nitropropan
FI854026L (fi) 2-fenylpyrano/2,3-b/pyridiner.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: SANDOZ S.A.

Effective date: 19870831